Comparative Pharmacology
Head-to-head clinical analysis: LORTAB versus TYCOLET.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LORTAB versus TYCOLET.
LORTAB vs TYCOLET
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydrocodone is a mu-opioid receptor agonist; acetaminophen inhibits cyclooxygenase (COX) and modulates pain pathways centrally.
Acetaminophen: COX-1/COX-2 inhibitor in CNS; Paracetamol: analgesic and antipyretic via central inhibition of prostaglandin synthesis.
1-2 tablets (each containing 5 mg hydrocodone/325 mg acetaminophen) orally every 4-6 hours as needed for pain. Maximum acetaminophen 3000 mg/day.
500-1000 mg orally or intravenously every 4-6 hours, maximum 4 g/day.
None Documented
None Documented
Hydrocodone: 3.3-4.4 hours in adults; prolonged in hepatic/renal impairment (up to 6-8 hours). Clinical context: requires 4-6 hour dosing intervals; steady-state in ~24 hours.
Terminal elimination half-life is 2-4 hours; prolonged in renal impairment (up to 12-24 hours in ESRD).
Renal: ~90% (unchanged: ~5% hydrocodone, ~60% hydromorphone and other conjugates; codeine-like metabolites). Biliary/fecal: minor (<10%).
Renal: 70-80% unchanged; Biliary/fecal: 10-15% as metabolites.
Category C
Category C
Opioid analgesic combination
Opioid analgesic combination